Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT200 and Finotonlimab in Recurrent or Metastatic HNSCC
NCT05552807Phase 1Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Jun 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sct200 and finotonlimab in head and neck squamous cell carcinoma (HNSCC) (4 cohorts), sponsored by Sinocelltech Group Limited. Primary endpoint: Objective Response Rate up to 24 months. Status: unknown.
02
Drugs
sct200finotonlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05552807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552807.